Introduction {#S5}
============

Preterm birth (PTB), defined as gestational age (GA) less than 37 weeks, is the leading cause of neonatal mortality and morbidity, with an estimated incidence of 5--12% depending on the geographic region([@R1]--[@R2]). The rate of PTB in Argentina in 2014 was estimated to be 8% (<http://deis.msal.gov.ar>). PTB is considered a complex and abnormal pregnancy outcome resulting from the interplay of several genetic and environmental factors([@R3]), and a history of a preterm delivery is the single greatest predictor of a future preterm delivery([@R4]). The role of other proposed predictors, such as maternal factors (e.g., short inter-pregnancy interval, multiple gestations), genetic mechanisms due high recurrence with previous PTB (e.g., familial aggregation), environment (e.g., low socio-economic status), or an interaction between these, remains largely unknown([@R5]).

Preterm birth is often categorized into sub-groups of varying severity. Subgroups are typically determined based on GA (Gestational Age) (i.e., GA\<32 weeks, GA= 32--36 weeks) or clinical presentation (idiopathic (PTB-I), preterm premature rupture of membranes (PTB-PPROM), or medical inducement (PTB-M)([@R6]). The clinical subtypes PTB-I and PTB-PPROM are together designated as spontaneous preterm birth (PTB-S). Given the heterogeneity observed in PTB, it is helpful to examine these categories separately with regard to etiology, prevention, and intervention([@R7]). However, differences among these preterm birth subtypes have not been fully explored in Latin American populations, and few epidemiological and genetic association studies of clinical subtypes in any population have been completed([@R8]--[@R10]).

In the current study, we attempted to replicate previous candidate gene associations that predispose individuals to specific clinical subtypes of PTB in a Latin American population([@R10]--[@R12]). Candidate gene associations in complex diseases, such as PTB, are frequently difficult to replicate, largely because of heterogeneity between populations and the unique characteristics of different study populations([@R13]). Specifically, the associated causative alleles often have different frequencies across diverse populations. Moreover, the contribution of genetic admixtures to PTB is not known, although significant racial differences exist in PTB([@R6], [@R10]). Genetic admixture studies with Latin American populations have demonstrated large geographic variability in the Amerindian and European contributions to Latin American ancestry. For example, an Argentine population was found to have extensive paternal directional mating between historic populations of European fathers and Amerindian mothers, resulting in a unique genetic admixture([@R14]--[@R15]). The aim of this genetic association study was to identify single nucleotide polymorphism (SNPs) associated with specific clinical subtypes of PTB in a Latin American population. Eighteen candidate genes were chosen for this work based on biological plausibility and previous associations with preterm birth([@R11], [@R16]). The current study was conducted at a single site in Argentina and included 709 preterm trios (neonate and parents).

Methods {#S6}
=======

The study procedures were approved by the Centro de Educación Médica e Investigaciones Clínicas (CEMIC) Ethics Committee (IRB 00001745 -- IORG 0001315) and the University of Iowa Institutional Review Board (IRB 200411759). Individuals were recruited from Nuestra Señora de la Merced Maternity Hospital in Tucumán-Argentina. Parents were recruited to the study and provided consent for themselves and the neonate. Neonatal samples were taken from placental cord blood, and parents provided a peripheral blood or saliva sample. Extraction of DNA from biological samples was completed at either CEMIC in Buenos Aires or the University of Iowa.

The current study included families of neonates born between July 2005 and December 2010. Inclusion criteria for the study were singleton neonates delivered at less than 37 weeks of gestational age. Neonates were excluded for the following reasons: congenital anomalies, multiple gestation, or maternal age less than 14 years. Cases were identified using the daily delivery room records (births were registered within 24 hours or in the immediate postpartum period).

Clinical subtypes {#S7}
-----------------

Three clinical subtypes were identified in accordance with recently developed research guidelines for conducting epidemiological genetic studies of PTB([@R1], [@R6]). The data on the onset of labor were regularly registered in the clinical perinatal record by the obstetrician. Based on this categorization, preterm deliveries at the hospital were classified by researchers as follows:

1.  PTB-I: preterm labor leading to PTB (idiopathic), diagnosed as cervical change (dilation and effacement) due to regular uterine activity. A rupture of membranes was only included in this category when the rupture occurred during active labor.

2.  PTB-PPROM: preterm premature rupture of the membranes diagnosed by pelvic examination or obvious leakage of fluid from the cervix into the posterior fornix. If it was unclear whether PPROM had occurred, an ultrasound was performed to identify oligohydramnios. Membrane rupture had to occur before the onset of labor regardless of the means of delivery.

3.  PTB-M: a medical condition existed that required delivery before 37 weeks gestation (i.e., preeclampsia).

The subtypes PTB-I and PTB-PPROM are together designated spontaneous preterm birth (PTB-S). The preterm births were classified into subtypes by two independent researchers. Cases were reviewed by the principal investigator if the independent researchers disagreed on the classification.

### Sample genotyping {#S8}

Twenty-four SNPs in 18 candidate genes (*F3*, *IL6R*, *KCNN3, CR1, FSHR, IL1B, FN1, COL4A3, PON1, TRAF2, F2, SERPINH1, PGR, IGF1*, *INF2*, *IGFIR*, *CRHR1*, *TIMP2*) were genotyped in the current cohort. Candidate genes were selected based on previous significant associations with PTB([@R10]--[@R12], [@R16]--[@R17]). Genotyping of SNP markers was performed using Taqman probes (Applied Biosystems, Foster City, California) and the Fluidigm SNP Genotyping platform (192.24 Dynamic Array) as previously described([@R18]).

All SNP genotyping assays were available and ordered using the Assay-on-Demand service from Applied Biosystems. These genotyping assays included primers to amplify the region containing the SNP of interest and two TaqMan Minor Groove Binder probes specific to the polymorphic variant alleles at the site labeled with different fluorescent reporter dyes, FAM and VIC. All reactions were performed using standard conditions supplied by Fluidigm. Following thermocycling, fluorescence levels of the FAM and VIC dyes were measured using the EP1 Reader and genotypes were scored using the Fluidigm Genotyping Analysis software.

Genotyping was completed on 709 preterm triads (mother-father-child). Genotypes were entered into a laboratory database (Progeny, South Bend, IN) to generate datasets for analysis.

### Data Analysis {#S9}

Genotyping quality controls were performed before completing the analysis (e.g., missing genotype rate by individual and by SNP, minor allele frequency (\<0.05), Hardy-Weinberg equilibrium failures for each SNP, and Mendelian Error rate) using PLINK software([@R19]). Alleles at each marker were tested for an association using Family Based Association (Transmission Disequilibrium Test (TDT)) to look for nonrandom allele transmission from parents to offspring([@R20]). The units of analysis were analyzed using PLINK software to investigate differences in transmission. The P values obtained in this study were corrected for multiple testing (Bonferroni correction P value \<0.00208 using an α of 0.05). However, given the exploratory nature of this initial study, less stringent values were also of interest. With 700 triads (mother-father-child), we reached a statistical power of 80% to identify a recessive allele that acts additively and increases the risk at least two-fold compared to a reference allele with a frequency of 10% in the population.

Results {#S10}
=======

We studied a total of 709 infant triads, of which 499 were classified as "spontaneous" (PTB-I+PTB-PPROM) and 210 as PTB-M. From PTB-S, 243 were classified as PTB-I, and 256 were classified as PTB-PPROM ([Table 1](#T1){ref-type="table"}). A complete list of the 24 SNPs and 18 candidate genes that were genotyped is shown in [Table 2](#T2){ref-type="table"}.

Using a TDT (Transmission Disequilibrium Test), we identified four SNPs associated with PTB that were nominally significant (p\<0.05) ([Table 3](#T3){ref-type="table"}). These SNPs were rs2272365 in *PON1* (p=0.002, OR=1.48, CI=1.15--1.90), rs610277 in *F3* (p=0.002, OR=1.96, CI=1.26--3.05), rs883319 in *KCNN3* (p=0.008, OR=1.32, CI=1.07--1.63), and rs4458044 in *CRHR1* (p=0.020, OR=1.21, CI=1.02--1.42). The association rs2272365 in PON1 was the only one that remained significant after a Bonferroni correction. The marker rs610277 in *F3* showed borderline significance after correction.

Three SNPs were associated with PTB-I (rs2272365 in *PON1* (p=0.005, OR=1.87, CI=1.20--2.91)*,* rs10178458 in *COL4A3* (p=0.015, OR=1.78, CI=1.11--2.85), and rs4458044 in *CRHR1* (p=0.041, OR=1.32, CI=1.01--1.73)), one SNP was associated with PTB-PPROM (rs610277 in *F3* (p=0.023, OR=2.30, CI=1.09--4.83)), and two SNPs were associated with PTB-M (rs883319 in *KCNN3* (p=0.006, OR=1.74, CI=1.17--2.59) and rs610277 in *F3* (p=0.015, OR=2.62, CI=1.16--5.93)) ([Table 3](#T3){ref-type="table"}). No associations remained significant after Bonferroni correction.

Discussion {#S11}
==========

Using a family-based approach, we found that three markers were nominally associated with PTB-I (*PON1*, *COL4A3*, and *CRHR1*), one marker (*F3*) was associated with PTB-PPROM, and two markers were associated with PTB-M (*F3* and *KCNN3*). These findings are consistent with previous literature, in that the SNPs associated with the clinical subtypes of PTB in this study are involved in at least one of the four main biological mechanisms that could lead to PTB: (i) activation of the maternal or fetal hypothalamic pituitary-adrenal axis, (ii) inflammation and infection, (iii) decidual hemorrhage, and (iv) uterine distention([@R21]).

A recent meta-analysis by Capece et al. (2014) used approximately 3600 cases and controls and analyzed 2175 SNPs in 274 genes for association with the PTB-Idiopathic and PTB-PPROM subtypes. Significant associations of PTB-I and PTB-PPROM were found for 248 SNPs in 102 genes and 39 SNPs in 32 genes, respectively ([@R2]). The authors propose an autoimmune/hormonal process for PTB-I and a hematologic/coagulation function disorder, collagen metabolism, matrix degradation and local inflammation for PTB-PPROM. Our study replicated the significant findings found for three of the markers associated with PTB-I (*PON1*, *COL4A3*, and *CRHR1*) and one of the markers associated with PTB-PPROM (F3).

*PON1* is involved in the decidual hemorrhage pathway and is thought to potentially activate biochemical mediators, such as matrix metalloproteinases (MMPs), which can in turn cause extracellular matrix (ECM) degradation and may lead to preterm birth via the initiation of early contractions, cervical ripening, and rupture of the PTB membranes([@R16]). Specifically, previous studies have hypothesized that mutations in *PON1* may indirectly activate thrombin and plasminogen cascades, which can result in ECM degradation, changes in the cervix, and rupture of the membrane([@R22]--[@R23]). Additionally, in vitro studies have shown that mutations in *PON1* are associated with changes in lipid profiles (HDL and LDL)([@R24]--[@R25]), and the incubation of endothelial cells with HDL increases the production of prostaglandin E2, leading to premature uterine contractions([@R26]). Thus, the findings of the current study support previous research indicating that genetic variation in *PON1* may lead to PTB-I.

The *COL4A3* gene encodes a structural protein that is a constitutive element of the extracellular matrix and is the main component responsible for maintaining the structure of the basement membrane of the amnion, chorion, and uterine cervix([@R27]). Previous work by Romero et al. (2010) used a haplotype analysis of genes (*COL4A3*, *IL6R*, *LTF* and *FGF1*) associated with PTB-I in a Hispanic population in Chile, and *COL4A3* emerged as the marker with the highest significance([@R11]). Therefore, previous and current work supports that variants in genes involved in extracellular matrix metabolism, such as collagen type IV alpha-3 chain (COL4A3) and degradation regulators of this structure (e.g., tissue inhibitor of metalloproteinase 2 (MMP-2)), could increase the risk of preterm labor.

CRHR1, which is involved in the receptor activity of the corticotropin releasing factor, was previously linked to preterm birth in a study by Bream et al. (2013)([@R17]). Importantly, plasma CRH levels increase exponentially during pregnancy, with a peak during childbirth, and women who deliver preterm have a more rapid increase in CRH levels in early pregnancy([@R28]) and in the last trimester of pregnancy. This suggests that the length of the gestational period may be predetermined and activated when CRH reaches its maximum expression and provides a plausible biological mechanism for the involvement of CRHR1in the etiology of preterm birth.

The PTB-PPROM subtype was associated with a marker in *F3. F3* or coagulation factor III is a membrane glycoprotein present in the fibroblasts of the wall of blood vessels and other cells. The placental decidua is rich in the tissue factor encoded by *F3*, which acts as the primary initiator of hemostasis([@R29]). Placental abruption (hemorrhage into the uterine decidua) is evident in the histological examination of over 60% of preterm births. After hemorrhage, the tissue factor binds to the membrane of the decidual cells and forms a complex with the activated factor VII, which in turn activates thrombin generated factor X. The binding of thrombin to its receptors enhances the production of enzymes that degrade the decidual and fetal membranes([@R30]). Additionally, thrombin binds to myo-metrial receptors, resulting in early uterine contractions. In sum, the tissue factor encoded by *F3* has been implicated in the degradation of placental membranes and the initiation of uterine contractions in PTB.

The etiology of PTB-M is difficult to establish because the determinants of this condition are very heterogeneous and include preeclampsia, fetal distress, small-for-gestational (SGA), and placental abruption([@R8]). Despite the limitations of this clinical subtype, the current study identified that a marker in *KCNN3* was associated with PTB-M. *KCNN3* is expressed in tissues responsible for maintaining gestation and inducing parturition([@R31]) and is subject to regulation by estrogen([@R32]), providing a feasible biological mechanism for *KCNN3* in the etiology of preterm labor([@R33]--[@R34]). Day and colleagues (2011) previously identified a significant association between markers in *KCNN3* and preterm birth([@R35]), and an associated study of Argentine women who delivered preterm identified the same marker as the current study([@R10]). Moreover, a study by Rada et al. (2012) utilized a mouse model and found that alterations in SK3 channel expression or function may incur a risk of cardiovascular-related disorders during pregnancy([@R36]). The KCNN3 channel is a key regulator of an angiogenic endothelium-mediated feedback pathway that must be properly regulated to maintain a successful pregnancy([@R37]). Disruption of this pathway can result in deleterious effects due to improper placental vascularization and thus may play a role in pregnancy disorders that increase the risk of preeclampsia and PTB.

The current study has several limitations that should be considered when interpreting the findings. First, the individuals were recruited from a single maternity hospital, as it was not possible to include different regions of the world for comparison, limiting the generalizability of the current findings. Second, only one marker maintained statistical significance after correction for multiple comparisons. However, it is known that associated studies of candidate genes in complex diseases such as PTB are frequently difficult to replicate, and this may be due to the genetic heterogeneity across populations.

A typical problem of genetic association studies with a case-control design is the identification of spurious associations due to bias from population stratification. Therefore, a family-based association study with more than 700 triads (mother-father-child) was used in this study to avoid this potential bias. The current study is one of the larger family-based studies of genetic associations with clinical subtypes of PTB in a Latin American population.

Conclusions {#S12}
===========

The current study suggests that different genetic influences are associated with the different clinical subtypes of preterm birth (PTB) in a Latin American population. The current approach allowed for the identification of SNPs specific to the different subtypes of PTB as well as SNPs shared by all subtypes of PTB. The SNPs in *PON1, COL4A3* and *CRHR1* were associated with the PTB-I subtype, an SNP in *F3* was associated with the PTB-PPROM subtype, and SNPs in *KCNN3* and *F3* were associated with the PTB-M subtype. These findings may lead to a better understanding of the pathophysiology of clinical subtypes of PTB and therefore better prevention of PTB. However, adding additional cohorts from different regions of Latin America is important to expand these findings to other populations and thus contribute more knowledge to the etiology of specific clinical subtypes of PTB.
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###### 

Demographic characteristics of the study population by clinical subtypes.

                                        PTB-I            PTB-PPROM        PTB-M            P value
  ------------------------------------- ---------------- ---------------- ---------------- ---------
  N (individuals/triads)                729/243          768/256          630/210          \-
  Maternal age (years)                  22.8 (+/− 5.6)   24.8 (+/− 6.2)   27.0 (+/− 6.4)   \<0.001
  Gestational age at delivery (weeks)   32.7 (+/− 3.2)   32.6 (+/− 2.9)   33.1 (+/− 2.7)   0.283
  Birth weight (grams)                  1871(+/− 566)    1811 (+/− 557)   1762 (+/− 579)   0.122
  Gestational age\<32 weeks N (%)       71 (29.1)        79 (30.9)        51 (24.3)        0.267
  Infant gender N (%male)               131 (53.7)       136 (53.3)       103 (49.0)       0.553

*NOTE*. PTB-I is PTB-Idiopathic; PTB-PPROM is PTB-Preterm Premature Rupture of Membranes; and PTB-M is PTB-Medically Indicated. ANOVA was used for continuous variables (maternal age, gestational age, and birth weight) and Pearson chi-square was used for dichotomized variables (gestational age \<32 and gender).

###### 

SNPs genotyped in the current study

  Gene name                                                                                            Gene symbol   Chr   SNPs                             MAF                   Functional consequence                        Encoded (Protein coding)
  ---------------------------------------------------------------------------------------------------- ------------- ----- -------------------------------- --------------------- --------------------------------------------- --------------------------------------------------------------------------------------
  Coagulation factor III precursor                                                                     *F3*          1     rs610277                         0.040                 Intron variant                                Surface glycoprotein
  Interleukin 6 receptor isoform 1                                                                     *IL6R*        1     rs8192282                        0.059                 Synonymous codon                              Interleukin 6 (IL6) receptor complex
  Potassium channel, calcium- activated, intermediate/small conductance, subfamily N alpha, Member 3   *KCNN3*       1     rs883319                         0.193                 Intron variant                                Small conductance calcium- activated potassium channel 3 (integral membrane protein)
  Complement component receptor 1                                                                      *CR1*         1     rs6691117                        0.336                 Missense                                      Monomeric single-pass type I membrane glycoprotein
  Follicle-stimulating hormone receptor                                                                *FSHR*        2     rs11686474                       0.438                 Intron variant                                Transmembrane receptor
  Interleukin 1, beta proprotein                                                                       *IL1B*        2     rs1143643                        0.262                 Intron variant                                Cytokineprotein Interleukin 1
  Fibronectin 1 isoform 3 preproprotein                                                                *FN1*         2     rs2304573                        0.428                 Intron variant                                Glycoprotein fibronectin
  Alpha 3 type IV collagen isoform 1                                                                   *COL4A3*      2     rs1882435; rs10178458            0.286; 0.105          Intron variant, Missense                      Type IV collagen, (multimeric protein composed of 3 alpha subunits)
  Paraoxonase 1                                                                                        *PON1*        7     rs854552; rs2272365              0.35; 0.126           UTR variant 3 prime, Intron variant           Enzyme paroxon (organophosphate)
  TNF receptor-associated factor 2                                                                     *TRAF2*       9     rs3750512; rs4880166             0.490; 0.392          Downstream variant 500B,utr variant 3 prime   TNF receptor associated factor 2
  Coagulation factor II, thrombin                                                                      *F2*          11    rs1799963                        0.003                 Downstream variant 500B,utr variant 3 prime   Coagulation factor II
  Serpin peptidase inhibitor, clade h, member 1                                                        *SERPINH 1*   11    rs667531                         0.306                 Upstream variant 2KB                          Glycoproteins that bind specifically to collagen type I
  Progesterone receptor                                                                                *PGR*         11    rs1942836                        0.363                 Possible regulatory regions                   Progesterone receptor, a member of the steroid receptor superfamily
  Insulin-like growth factor 1 (somatomedin C)                                                         *IGF1*        12    rs5742612                        0.139                 Intron variant,upstream variant 2KB           Hormone IGF1
  Inverted formin 2                                                                                    *INF2*        14    rs7153053                        0.343                 \-                                            Protein family called the formins
  Insulin-like growth factor 1 receptor                                                                *IGFIR*       15    rs7165181; rs4966038             0.402; 0.433          Intron variant                                Insulin-like growth factor I receptor (transmembrane receptor)
  Corticotropin-releasing hormone receptor 1                                                           *CRHR1*       17    rs7225082; rs4458044; rs173365   0.317; 0.374; 0.304   Intron variant                                Corticotropin-releasing hormone receptor
  Tissue inhibitor of metalloproteinase 2                                                              *TIMP2*       17    rs2277698                        0.113                 Synonymous codon                              Proteins inhibitors of the matrix metalloproteinases

Note. MAF: Minor Allele Frequency estimated from the sample studied. Chr is the chromosome number.

###### 

Candidate gene associations for PTB and clinical subtypes.

                      Informative N   Gene         SNP rs      A1   A2        Ratio T/UT[a](#TFN4){ref-type="table-fn"}   OR[b](#TFN5){ref-type="table-fn"}   CI[c](#TFN6){ref-type="table-fn"}         P value
  ------------------- --------------- ------------ ----------- ---- --------- ------------------------------------------- ----------------------------------- ----------------------------------------- ---------
  All PTB (N=709)     89              *F3*         rs610277    G    A         59/30                                       1.96                                1.26, 3.05                                0.002
  253                 *PON1*          rs2272365    G           T    151/102   1.48                                        1.15, 1.90                          0.00206[\*](#TFN7){ref-type="table-fn"}   
  358                 *KCNN3*         rs883319     T           C    204/154   1.32                                        1.07, 1.63                          0.008                                     
  584                 *CRHR1*         rs4458044    C           G    320/264   1.21                                        1.02, 1.42                          0.020                                     
  PTB-I (N=243)       86              *PON1*       rs2272365   G    T         56/30                                       1.87                                1.20, 2.91                                0.005
  75                  *COL4A3*        rs10178458   T           C    48/27     1.78                                        1.11, 2.85                          0.015                                     
  216                 *CRHR1*         rs4458044    C           G    123/93    1.32                                        1.01, 1.73                          0.041                                     
  PTB-PPROM (N=256)   33              *F3*         rs610277    G    A         23/10                                       2.30                                1.09, 4.83                                0.023
  PTB-M (N=210)       104             *KCNN3*      rs883319    T    C         66/38                                       1.74                                1.17, 2.59                                0.006
  29                  *F3*            rs610277     G           A    21/8      2.62                                        1.16, 5.93                          0.015                                     

*NOTE*. All N are numbers of triads; PTB-S is PTB-Spontaneous (PTB-I+PTB-PPROM); PTB-I is PTB-Idiopathic; PTB-PPROM is PTB-Preterm Premature Rupture of Membranes; PTB-M is PTB-Medically Indicated;

Ratio transmitted and un-transmitted alleles;

Odds ratio (risk of allele 2 (A2) in reference to Allele 1 (A1));

Confidence interval.

remained significant after correction for Bonferroni correction (p value \<0.00208)
